Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 5 of 7

'While having this biomarker would be a valuable advance, even without it we are able to run studies based on well-defined endpoints that evaluate disease progression,' says Sarah Noonberg, chief medical officer at Prothena

Sarah Noonberg, chief medical officer at Prothena, says that having a biomarker for Lewy bodies would be a valuable advance

Source  Courtesy of Sarah Noonberg